U3-1287
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for U3-1287, covering 2017-10-18 to 2021-06-16. Get the full timeline:
Most recent: Clinical Trial Update: Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]